The Impact of the Rs1044457 Polymorphism in the CMPK1 Gene on the Response Rate to Gemcitabine‐Based Chemotherapy in Metastatic NSCLC Patients
Abstract This study aims to evaluate the role of a specific gene polymorphism, Cytidine/Uridine Monophosphate Kinase 1 (CMPK1) rs1044457, in predicting the response to gemcitabine‐based chemotherapy in patients with NSCLC. A total of 98 NSCLC patients are enrolled in the study. Based on their respon...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Advanced Genetics |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ggn2.202400058 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849321158798737408 |
|---|---|
| author | Ghassan Saod Saleh Fouad Kadhim Gatea Qasim Sharhan Al‐Mayah Hayder Lazim |
| author_facet | Ghassan Saod Saleh Fouad Kadhim Gatea Qasim Sharhan Al‐Mayah Hayder Lazim |
| author_sort | Ghassan Saod Saleh |
| collection | DOAJ |
| description | Abstract This study aims to evaluate the role of a specific gene polymorphism, Cytidine/Uridine Monophosphate Kinase 1 (CMPK1) rs1044457, in predicting the response to gemcitabine‐based chemotherapy in patients with NSCLC. A total of 98 NSCLC patients are enrolled in the study. Based on their response, patients are classified as either responders or non‐responders. Specific primers are designed to amplify the rs1044457 variant and performed genotyping using restriction fragment length polymorphism (RFLP). The rs1044457 variant showed a statistically significant difference in frequency between responder and non‐responder patients. The mutant genotype (TT) is more frequent in non‐responder patients (18.75%) compared to responder patients (4%), with an odds ratio [OR] of 5.93 (95% confidence interval [CI] = 1.16–30.25, p = 0.032). Additionally, at the allelic level, the mutant allele (T) is more common in non‐responder patients (36.46%) compared to responder patients (23%), with a statistically significant odds ratio of 1.92 (95% CI = 1.03–3.58, p = 0.040). The findings of this study suggest that the mutant allele (allele T) of the rs1044457 variant may serve as a risk factor for resistance to gemcitabine‐based chemotherapy in patients with NSCLC. |
| format | Article |
| id | doaj-art-2e739efad71b4404a126f99ade9c07c7 |
| institution | Kabale University |
| issn | 2641-6573 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Genetics |
| spelling | doaj-art-2e739efad71b4404a126f99ade9c07c72025-08-20T03:49:50ZengWileyAdvanced Genetics2641-65732025-06-0162n/an/a10.1002/ggn2.202400058The Impact of the Rs1044457 Polymorphism in the CMPK1 Gene on the Response Rate to Gemcitabine‐Based Chemotherapy in Metastatic NSCLC PatientsGhassan Saod Saleh0Fouad Kadhim Gatea1Qasim Sharhan Al‐Mayah2Hayder Lazim3Ministry of Health, Salahuddin Health Directory Al‐Alam General Hospital Salahuddin IraqDepartment of Pharmacology and Therapeutics College of Medicine Al‐Nahrain University Baghdad IraqMedical Research Unit College of Medicine Al‐Nahrain University Baghdad IraqFaculty of Health Social Care and Medicine (FHSCM) School of Medicine Edge Hill University Ormskirk L39 4QP UKAbstract This study aims to evaluate the role of a specific gene polymorphism, Cytidine/Uridine Monophosphate Kinase 1 (CMPK1) rs1044457, in predicting the response to gemcitabine‐based chemotherapy in patients with NSCLC. A total of 98 NSCLC patients are enrolled in the study. Based on their response, patients are classified as either responders or non‐responders. Specific primers are designed to amplify the rs1044457 variant and performed genotyping using restriction fragment length polymorphism (RFLP). The rs1044457 variant showed a statistically significant difference in frequency between responder and non‐responder patients. The mutant genotype (TT) is more frequent in non‐responder patients (18.75%) compared to responder patients (4%), with an odds ratio [OR] of 5.93 (95% confidence interval [CI] = 1.16–30.25, p = 0.032). Additionally, at the allelic level, the mutant allele (T) is more common in non‐responder patients (36.46%) compared to responder patients (23%), with a statistically significant odds ratio of 1.92 (95% CI = 1.03–3.58, p = 0.040). The findings of this study suggest that the mutant allele (allele T) of the rs1044457 variant may serve as a risk factor for resistance to gemcitabine‐based chemotherapy in patients with NSCLC.https://doi.org/10.1002/ggn2.202400058CMPK1 gene polymorphismgemcitabine response ratenon‐small cell lung cancerrs1044457 polymorphism |
| spellingShingle | Ghassan Saod Saleh Fouad Kadhim Gatea Qasim Sharhan Al‐Mayah Hayder Lazim The Impact of the Rs1044457 Polymorphism in the CMPK1 Gene on the Response Rate to Gemcitabine‐Based Chemotherapy in Metastatic NSCLC Patients Advanced Genetics CMPK1 gene polymorphism gemcitabine response rate non‐small cell lung cancer rs1044457 polymorphism |
| title | The Impact of the Rs1044457 Polymorphism in the CMPK1 Gene on the Response Rate to Gemcitabine‐Based Chemotherapy in Metastatic NSCLC Patients |
| title_full | The Impact of the Rs1044457 Polymorphism in the CMPK1 Gene on the Response Rate to Gemcitabine‐Based Chemotherapy in Metastatic NSCLC Patients |
| title_fullStr | The Impact of the Rs1044457 Polymorphism in the CMPK1 Gene on the Response Rate to Gemcitabine‐Based Chemotherapy in Metastatic NSCLC Patients |
| title_full_unstemmed | The Impact of the Rs1044457 Polymorphism in the CMPK1 Gene on the Response Rate to Gemcitabine‐Based Chemotherapy in Metastatic NSCLC Patients |
| title_short | The Impact of the Rs1044457 Polymorphism in the CMPK1 Gene on the Response Rate to Gemcitabine‐Based Chemotherapy in Metastatic NSCLC Patients |
| title_sort | impact of the rs1044457 polymorphism in the cmpk1 gene on the response rate to gemcitabine based chemotherapy in metastatic nsclc patients |
| topic | CMPK1 gene polymorphism gemcitabine response rate non‐small cell lung cancer rs1044457 polymorphism |
| url | https://doi.org/10.1002/ggn2.202400058 |
| work_keys_str_mv | AT ghassansaodsaleh theimpactofthers1044457polymorphisminthecmpk1geneontheresponseratetogemcitabinebasedchemotherapyinmetastaticnsclcpatients AT fouadkadhimgatea theimpactofthers1044457polymorphisminthecmpk1geneontheresponseratetogemcitabinebasedchemotherapyinmetastaticnsclcpatients AT qasimsharhanalmayah theimpactofthers1044457polymorphisminthecmpk1geneontheresponseratetogemcitabinebasedchemotherapyinmetastaticnsclcpatients AT hayderlazim theimpactofthers1044457polymorphisminthecmpk1geneontheresponseratetogemcitabinebasedchemotherapyinmetastaticnsclcpatients AT ghassansaodsaleh impactofthers1044457polymorphisminthecmpk1geneontheresponseratetogemcitabinebasedchemotherapyinmetastaticnsclcpatients AT fouadkadhimgatea impactofthers1044457polymorphisminthecmpk1geneontheresponseratetogemcitabinebasedchemotherapyinmetastaticnsclcpatients AT qasimsharhanalmayah impactofthers1044457polymorphisminthecmpk1geneontheresponseratetogemcitabinebasedchemotherapyinmetastaticnsclcpatients AT hayderlazim impactofthers1044457polymorphisminthecmpk1geneontheresponseratetogemcitabinebasedchemotherapyinmetastaticnsclcpatients |